Aarti Pharmalabs Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has consistently been profitable over the last 5 years
- Latest quarter profit grew 53.8% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.22x)
- Working capital cycle has improved - days down from 115 to 92
- Company maintains a comfortable, low leverage position
CONS
- Recent results are weak - TTM profit is down 21.7% versus prior year
- Promoter holding has decreased over last 2 years: -3.6pp
- Receivables are growing faster than sales - a possible quality concern
- Total debt has risen sharply - up 73.0% year on year
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| AARTIPHARM | 828.85 | 35.26 | 7516.00 | 0.42 | 76.14 | 53.82 | 535.80 | 38.74 | 10.77 | 26.78 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 | |
| 373 | 352 | 353 | 388 | 459 | 364 | 409 | 421 | 291 | 344 | 330 | 470 | 443 | |
| Operating Profit | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 143 | 95 | 75 | 102 | 113 | 93 |
| OPM % | 18.52% | 20.01% | 21.32% | 23.24% | 17.36% | 20.45% | 23.91% | 25.39% | 24.66% | 17.86% | 23.67% | 19.42% | 17.40% |
| 0 | 1 | 1 | 2 | 2 | 4 | 5 | 1 | 2 | 0 | -3 | 8 | 0 | |
| Interest | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 |
| Depreciation | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 |
| Profit before Tax | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 67 | 39 | 58 | 76 | 101 |
| Tax % | 26.38% | 22.61% | 28.53% | 31.85% | 24.73% | 23.90% | 26.47% | 22.93% | 23.72% | 27.38% | 25.73% | 26.99% | 24.66% |
| Net Profit | 0 | 0 | 0 | 0 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.40 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 | |
| 0 | 995 | 1,603 | 1,467 | 1,651 | 1,450 | 1,586 | |
| Operating Profit | -0 | 205 | 342 | 386 | 464 | 369 | 383 |
| OPM % | — | 17.11% | 17.58% | 20.84% | 21.96% | 20.29% | 19.47% |
| 0 | 4 | 2 | 5 | 10 | 7 | 5 | |
| Interest | 0 | 12 | 21 | 17 | 27 | 47 | 53 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 104 | 112 |
| Profit before Tax | -0 | 155 | 261 | 300 | 361 | 233 | 275 |
| Tax % | -0.00% | 21.32% | 25.80% | 27.82% | 24.48% | 24.99% | 25.92% |
| Net Profit | -0 | 122 | 193 | 217 | 272 | 175 | 203 |
| EPS | -0.18 | 13.49 | 21.35 | 23.93 | 30.06 | 19.27 | — |
| Dividend Payout % | 0.00% | 0.00% | 9.37% | 12.53% | 16.64% | 18.16% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -2%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -3%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 25%
- 1 Year:
- -9%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 14%
- 3 Years:
- 12%
- Last Year:
- 9%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0 | 45 | 45 | 45 | 45 |
| 1,341 | 1,513 | 1,711 | 1,943 | 2,076 | |
| 340 | 214 | 281 | 416 | 734 | |
| Trade Payables | 215 | 340 | 378 | 278 | 335 |
| 144 | 132 | 166 | 221 | 291 | |
| Total Liabilities | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| 782 | 926 | 1,033 | 1,137 | 1,437 | |
| Capital Work in Progress | 165 | 62 | 78 | 307 | 305 |
| 32 | 87 | 107 | 77 | 194 | |
| 475 | 602 | 643 | 588 | 640 | |
| 0 | 0 | 519 | 575 | 583 | |
| Cash & Bank | 83 | 12 | 24 | 9 | 10 |
| 502 | 555 | 177 | 211 | 312 | |
| Total Assets | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 0 | -23 | 312 | 216 | 330 | 262 | |
| Cash from Investing | 0 | -139 | -158 | -215 | -412 | -431 |
| Cash from Financing | 0 | 260 | -163 | 10 | 65 | 171 |
| 0 | 78 | -71 | 12 | -17 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-02 - Aarti Pharmalabs Limited has informed the Exchange about General Updates
2026-08-31 - Aarti Pharmalabs Limited has informed the Exchange about Resignation of Director/KMP/SMP
2026-08-31 - Aarti Pharmalabs Limited has informed the Exchange about change in Management
2026-08-30 - Aarti Pharmalabs Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-29 - Aarti Pharmalabs Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for FY 2025-26'.
2026-08-29 - Aarti Pharmalabs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 22, 2026
2026-08-18 - Aarti Pharmalabs Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-17 - Aarti Pharmalabs Limited has informed the Exchange that Record date for the purpose of Dividend is 15-Sep-2026.
2026-08-17 - Aarti Pharmalabs Limited has informed the Exchange about Transcript
News
Recent coverage and analyst commentary for AARTIPHARM
Loading news…
AI Stock Analyst
Aarti Pharmalabs Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account